콘텐츠로 건너뛰기
주식/증권 ➡️ 중립

IBRX Stock Outlook After Q1 Results and a New FDA Review

요약

ImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA review timing and execution risks.